Related Experiment Video

Updated: Jun 9, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a

Jolanta M Siller-Matula1, Kurt Huber, Günter Christ

  • 1Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Heart (British Cardiac Society)
|August 26, 2010
PubMed

Insights

A higher 600mg clopidogrel loading dose significantly reduces major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary intervention (PCI). This intensified regimen effectively lowers MACE risk without increasing major bleeding events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Clopidogrel enhances platelet inhibition, reducing ischemic events but increasing bleeding risk.
  • Optimizing clopidogrel loading doses is crucial for balancing efficacy and safety in interventional cardiology.

Purpose of the Study:

  • To compare the efficacy and safety of 300mg versus 600mg clopidogrel loading doses.
  • To evaluate outcomes in patients undergoing percutaneous coronary intervention (PCI) one month after therapy initiation.

Main Methods:

  • Systematic literature search across major databases (MEDLINE, EMBASE, CENTRAL, Web of Science).
  • Inclusion of randomized controlled trials and non-randomized studies with adjusted effect estimates.
  • Meta-analysis using a random-effect model to calculate risk ratios for MACE and major bleeding.

Main Results:

  • Seven studies including 25,383 patients were analyzed.
  • A 600mg clopidogrel loading dose showed a 34% relative risk reduction in MACE (RR=0.66).
  • The 600mg dose did not significantly increase the risk of major bleeding (RR=0.91).

Conclusions:

  • A 600mg clopidogrel loading dose is superior to 300mg in reducing MACE in PCI patients.
  • Intensified clopidogrel loading with 600mg improves cardiovascular event rates without a significant increase in major bleeding.
  • The findings support the use of a 600mg loading dose for one-month follow-up in PCI patients.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...